Control-IQ+自动胰岛素输注联合GLP-1受体激动剂在2型糖尿病成人中的附加获益
一项随机试验比较Control-IQ+自动胰岛素输注(AID)与继续原胰岛素方案联合持续葡萄糖监测(CGM组)在319例胰岛素治疗的2型糖尿病成人中的效果。其中143例(45%)基线使用GLP-1受体激动剂(GLP-1 RA)并在试验期间继续使用。在GLP-1 RA使用者中,AID组HbA1c较基线8.0±1.2%下降0.8%,较CGM组平均改善-0.5%(95%CI -0.8至-0.3,P<0.001),且体重无显著增加。
要点
- GLP-1 RA使用者中,AID较CGM组HbA1c平均改善-0.5%(95%CI -0.8至-0.3,P<0.001)。
- GLP-1 RA使用者中,AID在体重方面与CGM组无显著差异(0.9 kg,95%CI -0.2至2.1,P=0.10)。
- 非GLP-1 RA使用者中,AID较CGM组体重平均增加1.9 kg(95%CI 0.5至3.2,P=0.007)。
核心结论
- AID对广泛胰岛素治疗的2型糖尿病患者均有显著获益,包括已接受GLP-1 RA等指南导向治疗者。
- 在GLP-1 RA使用者中,AID的附加获益包括HbA1c显著降低且胰岛素用量减少,同时血糖控制显著改善但体重无统计学增加。
研究设计与样本
- 随机试验,比较Control-IQ+ AID与继续原胰岛素输注方式联合CGM(CGM组)。
- 共319例胰岛素治疗的2型糖尿病成人,其中143例(45%)基线使用GLP-1 RA并在试验期间继续使用。
主要发现
- GLP-1 RA使用者中,AID组HbA1c较基线8.0±1.2%下降0.8%,较CGM组平均改善-0.5%(95%CI -0.8至-0.3,P<0.001)。
- GLP-1 RA使用者中,AID组在目标范围内时间(70-180 mg/dL)及其他反映高血糖的CGM指标上较CGM组有统计学显著改善。
- GLP-1 RA使用者中,AID组13周后体重与CGM组无显著差异(0.9 kg,95%CI -0.2至2.1,P=0.10)。
- 非GLP-1 RA使用者中,AID组较CGM组体重平均增加1.9 kg(95%CI 0.5至3.2,P=0.007)。
临床怎么用
- 对于已使用GLP-1 RA的胰岛素治疗2型糖尿病成人,加用Control-IQ+ AID可进一步改善血糖控制且不显著增加体重。
- 在GLP-1 RA使用者中,AID的附加获益包括HbA1c降低和胰岛素用量减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA). RESEARCH DESIGN AND METHODS: In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial. RESULTS: Among GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemia also showed comparable statistically significant improvements using AID when added to GLP-1 RA use. For GLP-1 RA users, there was no significant difference in weight after 13 weeks with AID compared with the CGM group (0.9 kg, 95% CI -0.2 to 2.1, P = 0.10), whereas, in GLP-1 RA nonusers, there was a mean weight gain of 1.9 kg with AID compared with CGM (95% CI 0.5 to 3.2, P = 0.007). CONCLUSIONS: The benefits of AID appear to be substantial for a broad spectrum of insulin-treated patients with type 2 diabetes, including those already receiving contemporary and guideline-directed therapy, such as a GLP-1 RA medication. These additive benefits of AID in GLP-1 RA users included significant reductions in HbA1c levels with simultaneous reduction in insulin use, along with no statistical increase in weight despite very significant improvements in glycemic control.
引用
- Graham TE, Raghinaru D, Afreen S, et al. Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes. Diabetes Care. 2025. PMID: 41264828. doi:10.2337/dc25-1753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。